Virus-like particle recombinant protein of virus variation strain VP2 gene of infectious bursal disease

Abstract

The invention relates to virus-like particle recombinant protein of a virus variation strain VP2 gene of an infectious bursal disease, belonging to the field of biologic pharmacy. The IBDV variation strain (AH1) VP2 gene is cloned, converted and transfected to obtain a recombinant baculovirus vBac-VP2; an infected Sf9 insect cell has specific fluorescence, and the antigen valence of the infected Sf9 insect cell is above 1.6*10<3>; the molecular weight of a recombinant VP2 protein is 53kDa, and the recombinant VP2 protein is in the state of virus-like particles; an indirect ELISA detection method established for an envelope antigen by the purified recombinant VP2 protein has good specificity and sensibility; an immune chicken can resist IBDV virulent attack, and the protection ratio achieves 100 percent. The novel virus-like particle recombinant VP2 protein prepared by the IBDV variation strain VP2 gene has high pertinence on the immune prevention of a current prevalent IBDV virulent strain and good practical value and popularization prospects.

Description

1. Technical field [0001] The invention relates to the expression and application of recombinant protein of VP2 gene virus-like particle of infectious bursal disease virus (IBDV) mutant strain (AH1), belonging to the field of biopharmaceuticals. 2. Background technology [0002] Infectious Bursal Disease (IBD) is one of the main infectious diseases that cause serious economic losses in the poultry industry in my country and the world. , especially the central immune organ-the bursa of Fabricius is the main feature of the infectious disease. The hazards of the disease include two aspects: one is to cause morbidity and death of chickens aged 3 to 8 weeks, especially in recent years, the emergence of a super-virulent strain (vvIBDV) has greatly increased the mortality of chicks; the other is that chickens are infected with the disease early , causing immunosuppression, resulting in increased susceptibility of chickens to other diseases and reduced or failed immune response to v...

AI Technical Summary

Problems solved by technology

At present, the safety and manufacturing process of conventional attenuated vaccines and inactivated vaccines are still insufficient: the use of medium and strong virulence live vaccines to prevent mutant strains has a relatively large biosafety problem, because different IBDV strains There is a possibility of gene reassortment between them, which brings hidden dangers to the prevention and control of the disease. Inactivated vaccines have difficulties in preparing antigens

The main problems in the current IBD genetic engineering vaccine research: either the expression level of the recombinant IBDV protein is not high enough, or the refolding of the recombinant IBDV protein is difficult, or the recombinant protein derived from one strain is not suitable for other mutant strains

Images